News and Updates

Glaucoma affects approximately three million individuals in the US and can lead to blindness if not treated. The current standard of care is to administer eye drops on a daily basis that results in a high level of patient non-compliance and the resulting series side effects. The first MIGS device…
Dr. Peter Hnik Appointed Chief Medical Officer Peter Hnik, MD, MHSc has been appointed Chief Medical officer of iVeena Delivery Systems Inc. Dr. Hnik will oversee the expansion of the iVeena clinical trials program and related regulatory issues. Dr. Hnik is an ophthalmologist by training and has had considerable corporate…
Alan Crandall, M.D. is considered a world authority in the research and treatment of glaucoma. Dr. Crandall has chaired more than 150 major national and international symposia. He has co-authored two text books and authored more than 200 peer reviewed articles. In addition he has trained 33 Glaucoma Fellows and…
Formation of iVeena Scientific Advisory Board: iVeena announces appointment of Edward Holland, MD., Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati, Stephen Lane, MD., Medical Director Associated Eye Care and Clinical Professor University of Minnesota Associated Eye Care, and Dr. Randall…
Dr. Jayakrishna Ambati, iVeena Vice President Advanced Ocular Design and Director, has been appointed a Fellow of the National Academy of Inventors. The NAI official appointment said "The NAI Fellows Selection Committee has chosen you for induction as you “have demonstrated a highly prolific spirit of innovation in creating or…
Dr. Bala Ambati presents "My Journey in Vision" at the the INK Conference. In association with TED, the INK Conference and INK Talks are India’s leading platform for spreading ideas, having featured eminent speakers and leading innovators of India.    
The University of Utah's "Technology & Venture Commercialization" profiled iVeena in its 2015 Annual Report. TVC at the U is dedicated to commercializing new technologies and inventions from discoveries made and developed at the U. READ THE EMAGAZINE VERSION(see pages 22-25) READ THE PDF VERSION(see pages 22-25)
iVeena announced that it has successfully completed its Series A financing. The iVeena financing was lead by the Park City Angels in cooperation with the Salt Lake Angels group. In addition, several nationally prominent ophthalmologists, physicians and the University of Utah Technology Venture Corporation contributed to filling out the round.…
Dr. Jayakrishna Ambati is Professor and Vice Chair of Ophthalmology and Visual Sciences, and Dr. E. Vernon & Eloise C. Smith Endowed Chair at the University of Kentucky. Dr. Ambati is a retinal surgeon with 15 years of experience. His research laboratory has made fundamental advances in age-related macular degeneration…
Dr. Patil brings more than 20 years of academic and pharmaceutical experience in Ophthalmology. Prior to joining iVeena, Dr. Patil worked at Alcon from 2004 to 2011 and at Novartis Institute of Biomedical Research from 2011 to 2013 as an Associate Director of Research and held number of roles including…
Sarah Molokhia has over 12 years in ocular drug delivery experience. Most recently, Sarah was working as a Research Consultant with Aciont, Inc. an ocular drug delivery company in clinical trials. After completing her B.S in pharmacy school, she achieved her Ph.D. in pharmaceutical chemistry, University of Utah under the…
Dr. Ambati was cited by The Ophthalmologist Magazine as the number one ophthalmologist in the world under 40 years of age for his contributions to ophthalmic research and humanitarian activities. Read complete article
iVeena completed a pre-IND call with the FDA delineating the clinical development pathway, required elements for the GLP study, and endpoints of a Phase 1/2a trial. The BDI would be treated as a drug and undergo the 505(b) pathway; iVeena would seek approval for treatment of post-cataract inflammation and potentially…
Mr. Simmons brings more than 30 years of large pharmaceutical and early stage drug development company experience. This experience includes several corporate licensing transactions, participation in several company financings and two successful Initial public Offerings. Most recently, Mr. Simmons held the position of corporate business development officer at Lipocine Inc.…
Mr. Burr has over 7 years of experience in ocular drug delivery and device development. From 2008 to 2009, Mr. Burr was a fellow at the Lassonde Entrepreneur Institute. Beginning in June 2009, Mr. Burr was hired as a Drug Delivery Scientist at iVeena where he oversaw drug delivery research…
iVeena has demonstrated safety and efficacy in 42 rabbit eyes in treating post-surgical inflammation and retinal thickening (as measured by optical coherence tomography). iVeena has also demonstrated appropriate and desired first-order release kinetics of dexamethasone. iVeena has been able to reproducibly manufacture implants using a method of hot-melt extrusion that…
Page 2 of 2